GlassScriptPhysician profile
Danielle L Davis
NPI 1750959714
$1,866.54
in general payments reported to CMS, 2019-2025
30 companies · $641 in 2025
The $641 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $283 · 2023: $453 · 2024: $383 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.31 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $230.81 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.87 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $125.00 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $106.49 | 2023-2025 | |
| Abbvie INC. | $102.34 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $89.31 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.35 | 2021-2025 | Caplyta |
| Shield Therapeutics INC | $76.32 | 2024 | |
| Glaxosmithkline, LLC. | $74.71 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $63.46 | 2024-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $59.94 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $46.41 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $46.37 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $45.70 | 2022-2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $33.77 | 2021-2022 | |
| Antares Pharma, INC. | $33.24 | 2022-2024 | Xyosted |
| Eisai INC. | $26.61 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.54 | 2025 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.04 | 2023 | Relistor |
| Biogen, INC. | $19.98 | 2021 | |
| Seqirus USA INC | $18.90 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.72 | 2025 | Gvoke Hypopen |
| Evoke Pharma, INC. | $15.36 | 2022 | |
| Merck Sharp & Dohme LLC | $15.18 | 2024 | Dificid |
| Avvisto Therapeutics, LLC | $14.61 | 2025 | Cycloset |
| Halozyme INC | $13.16 | 2023 | |
| Astellas Pharma US INC | $13.00 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.